Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

FHS
March 5, 2024
9:50 am

EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

After Novartis’ Adakveo was pulled in Europe, the UK follows suit

Novartis is pulling Adakveo from the UK market as its clinical benefits no longer outweigh its risks, a month after the Medicines and Healthcare products

February 22, 2024

Focus on Core Competencies and Split-Off of Pentixapharm AG – Biotech Investments

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for

October 21, 2023

Lab experiment shows exactly how heat waves can put hearts into ‘oxygen debt’

When temperatures soar, so do heart attacks. Now, a lab experiment explains just how temperatures climbing into Fahrenheit’s three-digits can cause ischemia and potential heart

June 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.